LA JOLLA, Oct. 30 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. today announced that Dr. Neil Kurtz, President and Chief Executive Officer of TorreyPines, will present at two upcoming investor conferences:
* Rodman & Renshaw 8th Annual Healthcare Conference in New York on Monday, November 6th at 3:55 p.m., eastern. * CIBC World Markets 17th Annual Healthcare Conference in New York on Tuesday, November 7th at 10:55 a.m., eastern.
An audio webcast of both presentations will be available live. You can access the webcasts at: www.torreypinestherapeutics.com. An archived version of the remarks will also be available through the Company’s web site for a limited time following the conference.
About TorreyPines Therapeutics
TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company that discovers and develops small molecule drugs to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for migraine; chronic pain, including neuropathic pain; and cognitive disorders, including Alzheimer’s disease and cognitive impairment associated with schizophrenia. Further information is available at www.torreypinestherapeutics.com.
This press release contains and the presentations to be made by the company will contain forward-looking statements or predictions. Such forward-looking statements include statements regarding the potential of the company’s product candidates to treat certain diseases and disorders. Such statements are subject to numerous factors, risks, and uncertainties regarding development, regulatory approval and commercialization that may cause actual events or results to differ materially from the company’s current expectations, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors including that TorreyPines Therapeutics may not be able to execute its integration strategies or realize the expected benefits of its recently completed merger with Axonyx, Inc. These and other risks which may impact management’s expectations are described in greater detail in the registration statement on Form S-4, as amended, as filed with the Securities and Exchange Commission and Axonyx’s other SEC reports. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
TorreyPines Therapeutics, Inc.
CONTACT: Craig Johnson of TorreyPines Therapeutics, Inc., +1-858-623-5665,ext. 158, cjohnson@torreypinestherapeutics.com; or Media, PatriciaGarrison, +1-917-322-2567, pgarrison@RxIR.com, or Investors, Rhonda Chiger,+1-917-322-2569, rchiger@RxIR.com, both of Rx Communications, forTorreyPines Therapeutics, Inc.
Web site: http://www.torreypinestherapeutics.com/
